High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking. The 2025 meeting, with anticipated attendance of 100 participants, promises to open avenues and opportunities of collaboration on a variety of issues important to the nuclear medicine and molecular imaging community while allowing interaction and networking.
Over the course of four days, the High Country Nuclear Medicine Conference will offer 27 hours of content. No CE Credit will be offered at the 2025 Conference. The 2025 Conference will only be held in-person.
2025 Program
*All times are Mountain Time. Schedule Subject to Change.
Download the PDF version of the 2025 Program here.
Saturday, March 1, 2025
6:30 AM – 7:00 AM Breakfast with Vendors
7:00 AM – 9:30 AM Instrumentation, AI and Data Analysis in Nuclear Medicine
Session Chair: Hans Vija, PhD
Co-Chair: Nicolas A. Karakatsanis, PhD, DABSNM, SM’IEEE
Title:
Ultra-performance total-body PET multi-parametric imaging to monitor human physiology and diseases
Speaker: Nicolas A. Karakatsanis, PhD
Multi-modality Synergistic Imaging in Nuclear Medicine
Speaker: Andreas Kjaer, PhD, MD
Quantitative PET and SPECT Image Reconstruction powered by Artificial Intelligence
Speaker: Chi Liu, PhD
The advent of Digital Twins and Personalized Radiation Therapy with Dosimetry
Speaker: Arman Rahmim, PhD
Data Utilization for Nuclear Medicine Theranostics and Necessity for Standardization
Speaker:Julia Brosch-Lenz, PhD
Round-Table Discussion with Q&A
Speakers: All session moderators and speakers
1:00 PM – 3:00 PM Roundtable: Open Discussion on Prostate & Neuroendocrine, lessons learned and to be learned
Lead: Michael M. Graham, PhD, MD
4:00 PM – 7:30 PM Cardiology Session
Session Chair: Piotr Slmoka, PhD
Co-Chair: Panithaya Chareonthaitawee, MD
Title:
Carving New Trails in Cardiac PET: The Evolving Landscape of SPECT and PET MPI
Speaker:Mouaz al-Mallah, MD, MSc
Slopes Ahead: Are We Ready for Flurpiridaz and Other New PET Perfusion Tracers?
Speaker:Jamieson Burque, MD
Fresh Powder in PET MBF: What’s New on the Horizon?
Speaker:Panithaya Chareothaitawee, MD
Shredding the Data: AI Insights from PET/CT Attenuation Maps
Speaker: Piotr Slomka, PhD
Hitting the Slopes with New PET Tracers for Amyloid Imaging
Speaker: Sarah Cuddy, MD
Sunday, March 2, 2025
6:30 AM – 7:00 AM Breakfast with Vendors
7:00 AM – 9:30 AM Latest Developments in Pediatric Nuclear Medicine – Imaging & Therapy
Session Chair: Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI
Co-Chair: Alan Packard, PhD
Title:
Monitoring Pediatric Patients with Cancer Predisposition Syndromes with PET
Speaker: Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI
Why are PET and SPECT images essential for pediatric epilepsy evaluation?
Speaker:Maria Rosana Ponisio, MD
New Therapeutic Options for Recurrent Neuroblastoma, from small molecules to antibodies
Speaker:Alan Packard, PhD
Early experience with EFOV PET CT in a pediatric oncology population
Speaker:Barry Shulkin, MD
1:00 PM – 3:00 PM Roundtable: SIRT
Lead: Michael Wissmeyer, MD
4:30 PM – 6:00 PM Hal O’Brien Rising Star Session
Session Chair: Piotr Slomka, PhD
Co-Chair: Peter Conti, PhD, MD
Session: Coronary microvascular function and systemic inflammatory disorders: A novel marker of risk
Speaker: Brittany Weber, PhD
Session: Advancing Radiopharmaceutical Therapies for Equitable Patient Care
Speaker: Carlos Uribe, PhD
6:00 PM – 7:00 PM Past President Discussion of the future of Nuclear Medicine
Moderator: Alan Packard, PhD
Top Reasons to attend:
– Where the Society was vs Where it is going?
– Where is the future in nuclear medicine?
– How to become the next SNMMI President.
– Where are we getting the next generation of Nuclear Medicine Practitioners?
Past Presidents:
Helen Nadel, MD FRCPC (Diag Rad) (Nuc Med), ABR (Ped Rad), ABNM, FACNM, FSNMMI
Peter Conti, PhD, MD
Michael Graham, PhD, MD
Alan Packard, PhD
Richard Wahl, MD, FACR
Cathy Cutler, PhD, FSNMMI
Satoshi Minoshima, PhD, MD
7:00 PM – 9:00 PM Sunday Night Dinner & Hal O’Brien Rising Star Award Ceremony. Open to all in-person attendees with meeting registration. Additional tickets available for guests.
Monday, March 3, 2025
6:30 AM – 7:00 AM Breakfast with Vendors
7:00 AM – 9:30 AM Regulatory Session
Session Chair: Ira Goldman, MA
Co-Chair: Cathy Cutler, PhD, FSNMMI
Title:
SNMMI Government Affairs Activities
Speaker: Cathy Cutler, PhD, FSNMMI
AI Landscape – From Approval to Reimbursement
Speaker: Munir Ghesani
TBD
Speaker: Chris Ignace
NRC Rulemaking and Guidance related to Nuclear Medicine
Speaker: Daniel Shaw
1:00 PM – 3:00 PM Roundtable: Cognitive impairment: Nuclear Medicine in the Patient journey
Lead: Maria Rosana Ponisio, MD
4:00 PM- 7:30 PM Theranostic including Alpha trials #1 (cutting edge focus / radiobiology)
Session Chair: Andreas Kjaer, PhD, MD
Co-Chair: Richard Wahl, PhD, MD
Title:
Radiobiology of alpha and beta emitters: do we understand it?
Speaker: Edward O’Neill, PhD
Which alpha emitter to pick: pros and cons beyond availability
Speaker: Andreas Kjaer, MD, PhD
Dosimetry in drug development and patient management
Speaker: Stephen A Graves, PhD
Radiolabeled monoclonal antibodies as theranostics revisited
Speaker: Richard Wahl, PhD, MD
Pretargeting for Radiotheranostics
Speaker: Andreas Kjaer, PhD, MD
Tuesday, March 4, 2025
6:30 AM – 7:00 AM Breakfast with Vendors
7:00 AM – 9:30 AM Theranostics #2 (clinical trial focus)
Session Chair: Richard Wahl, PhD, MD
Co-Chair: Andreas Kjaer, PhD, MD
Title:
Will We Have Sufficient Alpha and Beta Therapeutic Radionuclides to Meet Demand?
Speaker: Roy Brown, BS, MBA
Targeted Alpha Therapy (TAT) in SSTR expressing neuroendocrine tumors with Pb-212-DOTAMTATE (AlphaMedix ™), in PRRT naïve and progressed settings- The latest Phase II results
Speaker: Ebrahim Delpassand, MD
Initial Clinical Experience with Pb212 VMT alpha NET in patients with Neuroendocrine Tumors: Feasibility, Toxicity, and early Clinical Results
Speaker: Vikas Prasad, PhD
The first-in-human, phase I study of an actinium-225-labeled antibody targeting human kallikrein 2 in patients with metastatic castration-resistant prostate cancer
Speaker: Won Kim
Panel Discussion
1:00 PM – 3:00 PM Roundtable: Dosimetry & Post Treatment Spect
Lead: Michael Graham, PhD, MD and Richard Wahl, PhD, MD
4:00 PM- 7:30 PM Neurology Session
Session Chair: Andrew Stephens, PhD, MD
Co-Chair: Neil Vasdev, Ph.D., ACSF, FRSC (UK), FSNMMI
Title:
Revised Criteria for Diagnosis and Staging and their clinical implications
Speaker: Mary Ellen Koran, PhD, MD
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
Speaker: Renaud La Joie, PhD
Recent Progress for Imaging Traumatic Brain Injuries
Speaker: Carmela Tartaglia, MD, FRCPC
AD: one year after disease modification therapy and its reimbursement
Speaker: Ana Franceschi, PhD, MD
Dominantly Inherited Alzheimer’s Disease
Speaker: Tammy Benzinger, PhD, MD
PET imaging in non-AD neurodegeneration
Speaker: Maura Malpetti, PhD
Download the PDF version of the 2025 Program here.